连续五轮结直肠癌粪便免疫化学检测筛查的依从性参与结果
在意大利一项区域性每两年一次FIT筛查项目中,对494187名首轮参与者随访5轮(2005-2016),阳性阈值20微克血红蛋白/克粪便。仅依从者纳入分析,比较第1、3、4、5轮与第2轮的性能指标。结果显示第2至第3轮间多项指标显著下降20%-30%,腺瘤检出率和阳性预测值在第4、5轮趋于稳定。
要点
- 第2至第3轮间,男性FIT阳性比例从5.2%降至4.3%,下降20%-30%。
- 进展期腺瘤检出率从13.4降至10.2/1000,结直肠癌从1.7降至1.4/1000。
- 腺瘤检出率和阳性预测值在第4、5轮趋于稳定。
核心结论
- 这些发现支持FIT筛查可阻止一部分进展期腺瘤进展的观点。
- 筛查强度可基于既往轮次结果通过风险分层策略进行调节。
研究设计与样本
- 对意大利一项区域性每两年一次FIT筛查项目首轮的494187名参与者随访5轮(2005-2016)。
- FIT阳性阈值20微克血红蛋白/克粪便,每轮仅依从参与者纳入分析。
- 采用多变量泊松回归模型的率比和多分类逻辑回归模型的相对风险比,比较第1、3、4、5轮与第2轮(首个发病轮)的性能指标。
主要发现
- 第2至第3轮间,男性FIT阳性比例从5.2%降至4.3%,下降20%-30%。
- 第2至第3轮间,进展期腺瘤检出率从13.4降至10.2/1000,结直肠癌从1.7降至1.4/1000,进展期肿瘤从15.1降至11.6/1000。
- 第2至第3轮间阳性预测值下降10%或以下。
- 腺瘤检出率和阳性预测值在第4、5轮趋于稳定;进展期腺瘤、结直肠癌和进展期肿瘤的阳性预测值在第4、5轮男性和女性中略有下降。
- 近端结肠癌检出率在第2轮后稳定,远端结肠癌检出率在男性中至第4轮下降(从0.7降至0.3/1000),在女性中至第5轮下降。
关键数值与推荐
- FIT阳性阈值20微克血红蛋白/克粪便。
- 筛查间隔为每两年一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We investigated the magnitude and temporal patterns of the decreasing trend in main performance measures of fecal immunochemical test (FIT) screening for colorectal cancer (CRC) observed in second and subsequent rounds. METHODS: We followed up 494,187 participants from the first round of a regional biennial FIT screening program in Italy (cut-off value for positivity, 20 μg hemoglobin/g feces) for 5 total rounds (2005-2016). At each round, only compliant participants were eligible. Performance measures from the first, third, fourth, and fifth rounds were compared with those from the second round (the first incidence round) using rate ratios from multivariate Poisson regression models and relative risk ratios from multinomial logistic regression models. RESULTS: Between the second and the third rounds, a significant 20% to 30% decrease was found in the proportion of men with a positive FIT result (from 5.2% to 4.3%) and in detection rates of advanced adenoma (from 13.4 to 10.2 per 1000), CRC (from 1.7 to 1.4 per 1000), and advanced neoplasia (from 15.1 to 11.6 per 1000). Positive predictive values (PPVs) decreased by 10% or less between the second and third rounds. Detection rates and PPVs for adenoma stabilized by the fourth and fifth rounds. The PPVs for advanced adenoma, CRC, and advanced neoplasia decreased slightly in men and women by the fourth and fifth rounds. The detection rate of proximal colon cancer stabilized after the second round, whereas the detection rate of distal colon cancer decreased until the fourth round in men (from 0.7 to 0.3 per 1000), and the fifth round in women. CONCLUSIONS: These findings support the notion that FIT screening prevents progression of a subset of advanced adenomas. Screening intensity could be modulated based on results from previous rounds, with a risk-based strategy.
引用
- Baldacchini F, Bucchi L, Giuliani O, et al. Results of Compliant Participation in Five Rounds of Fecal Immunochemical Test Screening for Colorectal Cancer. Clin Gastroenterol Hepatol. 2020. PMID: 32827723. doi:10.1016/j.cgh.2020.08.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。